HansaBiopharma  Date:  [ADDRESS_1108339]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :    2018 -002 
1 (43) Clinical Study Protocol   
including non -substantial Amendment 0 3 
A prospective , observational long -term follow up  study of patients treated with 
imlifidas e (IdeS)  prior to kidney transplantation 
Study No.:  17-HMedIdeS -[ADDRESS_1108340]:  NA  
Phase:  Prospective , follow up  study  
EudraCT Number:  NA 
IND Number:  128074  
Name [CONTACT_2259]:  Hansa  Biophar ma.AB. Box [ADDRESS_1108341] be restricted to relevant parties.  
HansaBiopharma  Date:  [ADDRESS_1108342]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
2 (43) Protocol Revision  History including  Summary of Changes  
Version  Date  Overall  Rational for Changes  
Version  1.0 03 APR 2018          N/A Original Protocol  
Version 2.0  20 JUN 2018  • Assessment of Quality of Life Questionnaires were changed, it was 
decided to use two ins tead of three questionnaires.  
• Kidney biopsy data will be recorded directly in CRF in tsead of 
retrieved from the biopsy reports.  
• Any version of Banff classification can be used for classification of 
acute rejection epi[INVESTIGATOR_1841].  
• EudraCT number on first page is removed since the study was not 
submitted to any European regulatory authority . 
 
 
 
Version 3.0  
 
 27 SEP 2020  • The method of data collection will be  changed from paper CRF 
to electronic CRF .  
• A study visit can be performed remotely  if a subject is not able to 
visit the site.   
• Clarify the wordings “acute rejection epi[INVESTIGATOR_1865]” and “DSA 
rebound” by [CONTACT_802886] “graft rejection epi[INVESTIGATOR_1865]”.  
• Clarify that creatinine and proteinuria results from graft 
rejection epi[INVESTIGATOR_802872] [ADDRESS_1108343].  
Version 4.0  22 NOV 2021  • Updates due to change in CRO responsible for SAE and S[LOCATION_003]R 
handling . 
See Appendix 1 “Protocol Amendment History” for details of Amendment 03. 
HansaBiopharma  Date:  [ADDRESS_1108344]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
3 (43) Synopsis  
Name [CONTACT_790]/Company  
Hansa  Biopharma  AB (hereafter referred to as Hansa Biopharma ) 
Title of the stud y 
A prospective observational , long term  follow up  study of patients  treated with  imlifidase  prior to 
kidney transplantation  
Signatory  Coordinating  Investigator  (s) 
[CONTACT_802911] von Z ür-Muhle n  
Study Site (s) 
Six sites  will be involved; [ADDRESS_1108345] visit (F SFV) Q2 [ADDRESS_1108346] visit (L SLV) Q3 [ADDRESS_1108347] received imlifidase  prior to 
kidney transplantation will provide important data to future prescribers and patients of the potential 
long-term benefits of  imlifidase  mediated transplantation.  
Primary objective :  
Evaluation of graft survival in subject s who have undergone kidney transplantation after imlifidase  
administration.  
Secondary Objectives:  
• Evaluation of long -term clinical outcomes of transplanted subjects  treated with imlifidase  in terms 
of patient survival, kidney function, comorbidity, treatments and quality of life.  
• Assessment of safety blood sampling in transplanted subjects  treated with imlifidase  
• Assessment of donor specific antibodies (DSA) in transplanted subjects  treated with imlifidase  
• Assessment of immunogenicity (anti -drug antibodies , ADA ) in transplanted  subjects  treated with 
imlifidase  
Endpoint s 
The primary endpoint of this study is to determine overall graft survival, defined as time from 
transplantation to graft loss at 1, 2, [ADDRESS_1108348] dose of imlifidase .  
Graft loss is defined as: Permanent return to dialysis for at least 6 weeks, re -transplantation, or 
nephrectomy.  
HansaBiopharma  Date:  [ADDRESS_1108349]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
4 (43) Secondary Endpoints  
The following secondary endpoints will be evaluated at 1, 2, [ADDRESS_1108350] dose of 
imlifidase : 
• Overall patient survival (time from transplantation to death for any cause)  
• Kidney function as evaluated by [CONTACT_67889], P -creatinine, proteinuria  
• Number of graft  rejection epi[INVESTIGATOR_1841]  (Banff classification)  
• Safety laboratory tests   
• Treatment of graft rejection epi[INVESTIGATOR_1865]  
• Comorbidity  
• DSA levels  
• Presence of BK virus  
• ADA as evaluated by [CONTACT_14181] -imlifidase IgG  
• Health related quality of life as evaluated by [CONTACT_802887] a five year, long -term follow up, observational study.  The study will primarily determine the 
time of graft survival in subjects who have received imlifidase prior to kidney transplantation. 
Subjects that have participated, or are currently participating, in the imlifidase kidney 
transplantation studies  (called feeder studies)  13-HMedIdeS -02, 13 -HMedIdeS -03, 14 -HMedIdeS -
04 and 15 -HMedIdeS -06 will be included . The subjects will attend 4 follow up visits, 1, 2, 3 and 5 
years after imlifidase administration.  
Study Procedures/Assessments  
At all visits, g raft function (creatinine, eGFR, proteinuria) and time of graft survival will be 
assessed. Blood samples for analysis of DSAs, ADA and antibodies towards BK virus will be taken 
as well as total IgG and hematology samples. Information about  patient survival, comorbidity  
(infections, malignancy, diabetes mellitus and cardiovascular event s) and treatments of graft 
rejection epi[INVESTIGATOR_1865]  (dialysis, plasmapheresis, medications)  will be recorded.  The subjects will be 
asked to complete QoL questionnaire s.   
Number of subjects  
Up to 46 subjects will be included depending on subjects’ willingness to participate in the study.  
Diagnosis and main criteria for inclusion /exclusion   
Inclusion Criteria:  
1) Signed Informed Consent obtained before any study -related procedures  
2) Previous dosing with imlifidase followed by [CONTACT_802888]: 13 -HMedIdeS -02, 13 -HMedIdeS -03, 14 -HMedIdeS -04 or  
15-HMedIdeS -06 
Exclusion Criteria:  
1) Individuals deemed unable to comply with the protocol  
2) Inability by [CONTACT_802889]:  [ADDRESS_1108351]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
5 (43) Medicinal Product(S)  
Not applicable  
Statistical methods  
This is a long -term non -interventional study and for the evaluation and presentation o f data 
descriptive techniques will be used.  The data from the clinical assessments will be summarised by 
[CONTACT_802890]. Summary statistics (n, arithmetic mean, standard deviation, median, 
minimum and maximum values) will be presented for continuous variables. Counts and, if relevant, 
percentages will be presented for categorical variables.  The primary endpoint will be analy sed by 
[CONTACT_8761] -Meier survival method. There will be no formal statistical hypothesis or testing because 
of the observational nature of the study.  
HansaBiopharma  Date:  [ADDRESS_1108352]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
6 (43)  
Table of contents  
See Appendix 1 “Protocol Amendment History” for details of Amendment [ADDRESS_1108353] of Abbreviations  ................................ ................................ ................................ ..........  10 
1. Introduction  ................................ ................................ ................................ ..........  11 
1.1 Background  ................................ ................................ ................................ ............  11 
1.2 Rationale  ................................ ................................ ................................ ................  13 
1.3 Benefit / Risk Aspects  ................................ ................................ ............................  14 
2. Study Objectives and Endpoints  ................................ ................................ .........  14 
2.1 Objectives  ................................ ................................ ................................ ...............  14 
2.2 Endpoints  ................................ ................................ ................................ ...............  14 
3. Investigational Plan  ................................ ................................ ..............................  15 
3.1 Overall Study Design  ................................ ................................ .............................  15 
3.1.1  Overall Study Outline  ................................ ................................ ............................  16 
3.1.2  Follow up  Procedures  ................................ ................................ .............................  16 
3.2 Study Schedule  ................................ ................................ ................................ ....... 16 
3.3 Planned number of study sites and subjects  ................................ ...........................  16 
3.4 Planned End of Study  ................................ ................................ .............................  16 
4. Study Population  ................................ ................................ ................................ .. 16 
4.1 General  ................................ ................................ ................................ ...................  16 
4.2 Selection Criteria  ................................ ................................ ................................ .... 17 
4.2.1  Inclusion Criteria  ................................ ................................ ................................ .... 17 
4.2.2  Exclusion Criteria  ................................ ................................ ................................ .. 17 
4.3 Discontinuation of Subjects  ................................ ................................ ...................  17 
5. Study Procedures  ................................ ................................ ................................ . 17 
5.1 Study Visits  ................................ ................................ ................................ ............  17 
5.2 Flow Chart  ................................ ................................ ................................ ..............  19 
6. Study assessment s ................................ ................................ ................................  20 
6.1 Assessments related to Primary Endpoint  ................................ ..............................  20 
6.1.1  Graft Survival  ................................ ................................ ................................ .........  20 
6.2 Assessments related to Secondary Endpoints  ................................ ........................  20 
6.2.1  Patient survival  ................................ ................................ ................................ ....... 20 
HansaBiopharma  Date:  [ADDRESS_1108354]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
7 (43) 6.2.2  Kidney function  ................................ ................................ ................................ ...... 20 
6.2.3  Kidney biopsy  ................................ ................................ ................................ ........  20 
6.2.4  Graft rejection epi[INVESTIGATOR_1841]  ................................ ................................ .........................  20 
6.2.5  Treatment of graft rejection epi[INVESTIGATOR_1841]  ................................ ................................ ..... 20 
6.2.6  Comorbidity  ................................ ................................ ................................ ...........  21 
6.2.7  Donor Specific Antibodies (DSA)  ................................ ................................ .........  21 
6.2.8  Immunogenicity by [CONTACT_74939] -Drug Antibodies (ADA)  ................................ ................  21 
6.2.9  Health Related Quality of Life Questionnaire (HR -QoL)  ................................ ..... 21 
6.3 Safety and other Laboratory Samples  ................................ ................................ .... 21 
7. Biological Sampling Procedures  ................................ ................................ .........  22 
7.1 Handling, Storage and Destruction of Biological Samples  ................................ .... 22 
7.2 Chain of Custody of Biological Samples  ................................ ...............................  22 
7.3 Withdrawal of Informed Consent for Donated Biological Samples  ......................  22 
8. Adverse Events and Serious Adverse Events  ................................ ....................  23 
8.1 Definitions  ................................ ................................ ................................ ..............  23 
8.1.1  Adverse event  ................................ ................................ ................................ .........  23 
8.1.2  Serious adverse event  ................................ ................................ .............................  23 
8.2 Collection and Recording of Adverse Events  ................................ ........................  24 
8.2.1  Variables  ................................ ................................ ................................ ................  24 
[IP_ADDRESS]  Causality assessment  ................................ ................................ ..............................  24 
8.2.2  Adverse Events Based on Signs and Symptoms  ................................ ....................  25 
8.2.3  Adverse Events Based on Examinations and Tests  ................................ ...............  25 
8.2.4  Follow up of Unresolved Adverse Events  ................................ .............................  25 
8.2.5  Reporting of Serious Adverse Events  ................................ ................................ .... 25 
8.2.6  Reporting of Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs)  ........  [ADDRESS_1108355]  ................................ ................................ ........  26 
8.4 Pregnancy and Pregnancy  Outcome  ................................ ................................ ...... 26 
9. Study Management  ................................ ................................ ..............................  27 
9.1 Pre-study Activities  ................................ ................................ ................................  27 
9.2 Monitoring of the Study  ................................ ................................ .........................  27 
9.3 Source data verification  ................................ ................................ .........................  28 
9.4 Audit and Inspection  ................................ ................................ ..............................  28 
9.5 Study Agreements  ................................ ................................ ................................ .. 28 
HansaBiopharma  Date:  [ADDRESS_1108356]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
8 (43) 10. Data Management  ................................ ................................ ................................  29 
10.1  Case Report Form  ................................ ................................ ................................ .. 29 
10.2  Provider of Data Management  ................................ ................................ ...............  29 
10.3  Coding  ................................ ................................ ................................ ....................  29 
10.4  Handling of External Data  ................................ ................................ .....................  29 
11. Statistical Methods  ................................ ................................ ...............................  29 
11.1.1  Full Analysis Set (FAS)  ................................ ................................ .........................  [ADDRESS_1108357] disposition  ................................ ................................ ................................ . 30 
11.3.1  Demographics and Other Baseline Characteristics  ................................ ................  30 
11.3.2  Concomitant Medication  ................................ ................................ ........................  30 
11.3.3  Exposure and Compliance  ................................ ................................ .....................  30 
11.4  Statistical analysis of Primary Endpoint  ................................ ................................  30 
11.5  Primary endpoint – graft survival  ................................ ................................ ..........  [ADDRESS_1108358] or Planned Analyses  ................................ ..............  33 
12.1  Protocol Amendment(s)  ................................ ................................ .........................  33 
12.2  Protocol Deviations  ................................ ................................ ................................  33 
HansaBiopharma  Date:  [ADDRESS_1108359]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
9 (43) 12.[ADDRESS_1108360] of the Study  ................................ ................................ .................  34 
14.2  Liabilities and Insurance  ................................ ................................ ........................  35 
14.3  Independent Ethics Committee(s) and Institutional Review Boards (IRB)  ...........  35 
14.4  Regulatory Authority(ies)  ................................ ................................ ......................  [ADDRESS_1108361] of Figures  
Figure 1.Overall study outline  ................................ ................................ ..............................  16 
 
HansaBiopharma  Date:  [ADDRESS_1108362]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
10 (43) List of Abbreviations  
ADA  Anti-Drug Antibody  
AE Adverse Event  
CKD  Chronic Kidney Disease  
CRF  Case Report Form  
CRO  Contract Research Organization  
CTCAE  Common Terminology Criteria for Adverse Events  
DD Deceased Donor  
DSA  Donor Specific Antibodie s 
eGFR  estimated Glomerular Filtration Rate  
EQ-5D-5L European Quality o f Life -[ADDRESS_1108363]  
IVIg  Intravenous Immunoglobulin  
KDQOL -SF Kidney Disease Quality  of Life -Short Form  
KM Kaplan -Meier  
LD Living Donor  
MedDRA  Medical Dictionary for Regulatory Activities  
MFI Mean Florescence Intensity  
PE Plasma Exchange    
QA Quality Assurance  
RA Regulatory Authority  
SAB  Single Antigen Bead   
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SDV  Source Document Verification  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  
 
HansaBiopharma  Date:  [ADDRESS_1108364]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
11 (43) 1. INTRODUCTION  
The company code initially used in this project was HMED -IdeS (sometimes abbreviated to 
IdeS) and thus many reports refer to this name.  The International Nonproprietary Name (INN) 
imlifidase was recently assigned for the active substance and going forward this name [CONTACT_802909].  
1.1 Background  
Renal transplantation is the preferred treatment choice for patients with end stage kidney 
disease since it increases survival and patient quality of life and results in substantial savings 
in health care costs compared to dialysis  (Montgomery et al. 2005 ).  
Approximately one third of patients waiting for kidney transplantation are sensitized to 
human leukocyte antigen (HLA)  and sensitization hampers the identification of a suitable 
donor  (Iyer et al. 2014 ). The presence of strong HLA donor specific antibodies (DSAs) is a 
direct contraindication to transplantation because of the risk of hyper -acute antibody -mediated 
rejection with acute allograft loss. For transplant candidates who have antibodies, which react 
against a wide range o f HLA , it can be difficult to find a donor against whom they have no 
antibodies. This is true both for patients waiting for a deceased donor kidney and for those 
within a paired donation program who have an available live donor against which they have  
DSAs.  
Data demonstrate s that desensitization followed by [CONTACT_802891] s is 
clearly associated with short - and long-term survival benefits  compared to staying on dialysis  
(Montgomery et al. 2011 ; Vo et al. 2013 ; Orandi et al. 2014 ; Orandi et al. 2016 ). In addition, 
the patient’s quality of life is dramatically increased and there are substantial cost -savings 
associated with desensitization compared to dialysis  (Vo et al. 2013 ). 
Imlifidase is an IgG -degrading enzyme of Streptococcus pyogenes  that cleaves all four human 
subclasses of IgG with strict specificity . Cleavage of IgG generates one F(ab’) 2- and one 
homodimeric Fc -fragment and efficiently neutralizes Fc -mediated activities of IgG ( HMed 
doc. No. 2012 -003) (Wenig et al. 2004 ; Vincents et al. 2004 ; von Pawel -Rammingen et al. 
2002 ). Imlifidase -mediated IgG degradation constitutes a novel therapeutic principle for the 
treatment of IgG -driven human dise ases.  
Hansa Biopharma  AB has performed in vitro  studies and clearly demonstrated that imlifidase  
effectively cleaves purified IgG as well as IgG in serum from human and rabbit. Imlifidase  is 
very specific in that no other substrate has been found (HMed Doc. No. 2012 -003). In 
addition, imlifidase  treatment rapi[INVESTIGATOR_129124] -HLA IgG in serum from 
sensitized chronic kidney disease  (CKD ) grade 5 patients in vitro  (HMed Doc. No. 2012 -005). 
HansaBiopharma  Date:  [ADDRESS_1108365]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
12 (43) The reactivity to individual HLA -antigens was reduced below the critical Mean Florescence 
Intensity (MFI) acceptable for transplantation and a positive crossmatch test was turned into 
negative. Imlifidase  offers a unique and powerful approach for removing the impenetrable 
immunology barrier HLA antibodies present and would allow  potentially life-saving 
transplants to  highly  sensitized  patients who are currently not eligi ble for kidney 
transplantation.  
The clinical studies performed  or ongoing  with imlifidase  within the transplantation program 
are summarised i n Table 1. 
 
Table 1. Summary table of clinical studies with imlifidase  in the transplantation program . 
Study No / 
EudraCT No  Phase  / 
Subjects  Doses  / 
Follow up 
time  Main objectives  Comments  Status  / 
Country  /  
Subject  
Numbers  
11-HMedIdeS -01 / 
2012 -000 969 -21 I / 
Healthy 
subjects  0.010, 0.040, 
0.12 and 
0.24 mg/kg 
BW 
 
[ADDRESS_1108366]-in-man, double 
blind, randomized, 
single ascending 
dose, 20 active,  
9 placebo.  
IgG complete ly 
cleaved within 1 -2 h. 
Safe and well 
tolerated.  
 Completed  / 
SE / 
 
N=29  
13-HMedIdeS -02 / 
2013 -005417 -13  II / 
CKD 
Patients  0.12 and 
0.25 mg/kg 
BW given 
once or 
twice within 
48 h / 
 
64 d Efficacy in CKD 
patients defined as 
imlifidase  dosing 
scheme resulting in 
HLA antibody 
levels acceptable 
for transplantation, 
within 24 h from 
dosing.  
Safety in the 
transplantation 
setting.  
 Single arm with 
ascending doses.  
Primary efficacy 
endpoint reached.  
Safe and well 
tolerated.  
One patient was 
transplanted (not part 
of protocol). 
Deceased donor.  Completed  / 
SE / 
 
N= 8  
13-HMedIdeS -03 / 
2014 -000712 -34  II / 
Patients  0.25 and 0.5 
mg/kg  / 
 
180 d  Safety in the 
transplantation 
setting.  
Efficacy defined as 
HLA antibody 
levels acceptable 
for transplantation.  Similar design as 13 -
HMedIdeS -02 but 
transplantation part of 
protocol.  
Deceased and living 
donors. Safe and well 
tolerated.  All 
patients desensiti zed 
and transplanted  
 Completed  / 
SE / 
 
N=10  
HansaBiopharma  Date:  [ADDRESS_1108367]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
13 (43) Study No / 
EudraCT No  Phase  / 
Subjects  Doses  / 
Follow up 
time  Main objectives  Comments  Status  / 
Country  /  
Subject  
Numbers  
14-HMedIdeS -04 / 
EudraCT: NA 
IND 124301   II / 
Patients  0.24 and 0.5 
mg/kg /        
 
180 d  Safety in 
combination with 
Cedars Sinai’s 
“standard protocol” 
for desensitization 
of highly sensitized 
patients. Efficacy in 
prevention of 
ABMR.  Investigator 
sponsored IND.  
Imlifidase  combined 
with rituximab and 
IVIg. 
All transplantations 
successful except one 
graft loss which 
occurred due to non -
HLA and non -IgG 
ABMR.  Biopsy 
suggested rejection 
due to IgM and IgA.  
 Completed  / 
US / 
 
Total N= 17 
Analysis and 
reporting 
ongoing . 
 
 
15-HMedIdeS -06 / 
2016 -002064 -13 
IND: 128074  II / 
Patients  0.25 and 0.5 
mg/kg  /  
 
Primary 
endpoint:   
24 h  
Safety : 
[ADDRESS_1108368].  
Safety in the 
transplantation 
setting.  Deceased and living 
donors.  
Target population 
cannot be 
transplanted with 
current available 
methods for 
desensiti zation .  
All transplantations 
(18) were successful 
except one graft loss . 
For o ne patient,  
imlifidase  dosing was 
interrupted due to 
allergic reaction and 
the pat ient was not 
transplanted.  
 Ongoing  /   
US, F R & 
SE / 
 
Total N= 19 
Recruitment 
ended  15 
Dec 2017.  
 
BW=body weight, h=hours, d=days   
 
In completed (13 -HMedIdeS -02, 13 -HMedIdeS -03 and 14-HMedIdeS -04) and ongoing studie s 
(15-HMedIdeS -06), subjects  have been treated with imlifidase  and transplanted with kidney s 
from deceased or liv ing donors. The f ollow up periods were  [ADDRESS_1108369] received a kidney transplant following imlifidase  dosing to provide a better understanding 
regarding the long-term outcome for these subjects . Data  of parameters such as  patient  and graft  
survival, kidney function, comorbidity,  treatment of graft rejection epi[INVESTIGATOR_802873]-drug antibody levels will be collected.  
HansaBiopharma  Date:  [ADDRESS_1108370]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
14 (43) 1.3 Benefit  / Risk  Aspects  
The subject s included in this study have received imlifidase  prior to  kidney transplant ation  in 
previous clinical studies. The current study is performed to collect long -term follow up  data 
on graft function  and safety . Most of the assessments performed under the current protocol 
are already part of the follow  up within standard of care  for these subjects  and consequently 
they will not impose any additional risk.   
2. STUDY OBJECTIVE S AND ENDPOINTS  
2.[ADDRESS_1108371] ives include : 
• Evaluation of long -term clinical outcomes of transplanted subjects  treated with imlifidase  
in terms of  patient survival, kidney  function , comorbidity,  treatments  and quality of life . 
• Assessmen t of safety  blood sampling in transplanted subjects  treated with imlifidase  
• Assessment of donor specific antibodies ( DSA ) in transplanted subject s treated with 
imlifidase  
• Assessment of immunogenicity (anti-drug antibodies , ADA ) in transplanted subjects  treated  
with imlifidase  
2.[ADDRESS_1108372] dose of  imlifidase .  
Graft loss is defined as: Permanent  return to dialysis for at least [ADDRESS_1108373] ongoing dialysis period reported  (EMA Guideline on clinical investigation of 
immunosuppressants for solid organ transplantation 2008 ) . 
Secondary Endpoints  
The following secondary endpoints will be evaluated  after the first dose of imlifidase  at the 
time points 1, 2, 3  and 5 years : 
• Overall p atient  survival  defined as time from transplantation to death for any cause  
HansaBiopharma  Date:  [ADDRESS_1108374]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
15 (43) • Kidney  function  as evaluated by  [CONTACT_67889], P-creatinine , proteinuria   
• Number of graft  rejection  epi[INVESTIGATOR_1841]  (classified by [CONTACT_86599]  , (Haas et al. 2018 )) 
• Safety laboratory  tests (hematology , total IgG )   
• Treatment of graft rejection epi[INVESTIGATOR_1841]   
• Comorbidity   
• DSA levels as evaluated by [CONTACT_129148] -HLA  analysis  
• Presence of BK virus    
• ADA  as evaluated by [CONTACT_14181] -imlifidase IgG   
• Health related quality of life ( HR-QoL) as evaluated by [CONTACT_802892]-5D-
5L and KDQOL-SF. 
 
3. INVESTIGATIONAL PLAN  
3.[ADDRESS_1108375] participated, or 
are currently participating, in selected imlifidase  kidney transplantation studies (referred to as 
“feeder studies”) will be contact[CONTACT_802893]. The following studies will be considered feeder studies : 13-HMedIdeS -02, 13-
HMedIdeS -03, 14-HMedIdeS -04 and 15-HMedIdeS -06. Up to 46 subjects  will be included 
depending on subjects’  willingness to participate  in the study .  
The study will primarily determine the time of graft survival in subjects  who have received 
imlifidase  prior to kidney transplant ation . The subjects  will attend 4 follow up  visits, 1, 2, 3  and 
5 years  after imlifidase  administration. Some subjects  will not perform all 4 visits because  the 
study start will be after the  subjects’ first visit  should have taken place.   
Kidney  function (creatinine, eGFR, proteinuria) and graft survival will be assessed.  Graft  
rejection epi[INVESTIGATOR_802874] . Information from k idney biops ies 
performed within  standard of care will be collected.  Blood samples for analysis of  DSA s, ADA  
and antibodies  towards  BK virus will be taken  as well as  total IgG and safety hematology 
samples . Medical ly relevant c omorbidity  (infections, malignancy, diabetes  mellitus and 
cardiovascular events ) will be recorded. Information about treatment s of graft rejection 
epi[INVESTIGATOR_802875]  (dialysis, plasmapheresis , medications) . At all visits, t he subjects  will 
be asked to complete  QoL questionnaires .  The overall study outline is summarized  in Figure 
1. 
HansaBiopharma  Date:  [ADDRESS_1108376]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
17 (43) 4.[ADDRESS_1108377] meet all inclusion criteria and no exclusion criteria  to be eligible for the study .  
4.2.1 Inclusion Criteria  
• Signed Informed Consent obtained before any study -related  procedures  
• Previous dosing with imlifidase  followed by [CONTACT_802894]: 13 -HMedIdeS -02, 13 -HMedIdeS -03, 14-
HMedIdeS -04 or 15-HMedIdeS -06  
Note: The primary objective in this study is overall graft survival after imlifidase  
treatment  therefore t he subjects  can also be included in the event that  the subject did not 
fully complete the feeder study.   
4.2.2 Exclusion Criteria  
• Individuals deemed unable to comply with the protocol  
• Inability by [CONTACT_802895]  
4.[ADDRESS_1108378]’s withdrawal, if possible. The investigator also has the right to withdraw subjects . In 
either event, the investigator must  notify monitor.  
If a subject  prematurely discontinues participation , the End  of Study  Form  (with date and reason 
for discontinuation ) in the CRF  must be completed.  
 
5. STUDY PROCEDURES  
5.[ADDRESS_1108379]  be informed  about the study,  verbally and in writing , 
and give their written consent before any study procedure is performed. After informed consent 
is obtained, pre -study visit data such as information on graft survival and patient survival can 
be collected and entered in the CRF.   
Some subjects will not perform all 4 visits because the study start will be after the subjects’ first 
visit should have taken place.   
If a subject is not able to attend a  planned  visit at the  site, the visit can be performed remotely.  
The blood sampling should be  performed at the local laboratory  (if possible)  and QOL forms 
HansaBiopharma  Date:  [ADDRESS_1108380]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
18 (43) sent to the subject . The following activities and assessments will be performed at 1 year (+/ - 2 
months ), 2 years (+/ - 4 months ), 3 years (+/ - 4 months ) and 5 years (+/- 6 months ) post 
imlifidase dosing:  
• Check of inclusion and exclusion criteria will be performed at the first visit for each 
subject after 1, [ADDRESS_1108381] imlifidase dosing . 
• Subject s shall  complete QoL questionnaires (EQ-5D-5Land KDQOL-SF) 
• Evaluation of graft survival  
• Record patient survival (if applicable, date and cause of death)   
• Safety laboratory tests  (see Table 3) 
• P-creatinine, eGFR and U-proteinuria test s 
• DSA sample s 
• ADA sample  
• BK virus sample  
• Record  comorbidity  such as infections, malignancy, diabetes mellitus and 
cardiovascular events  
• Record graft  rejection epi[INVESTIGATOR_1841] (classified by [CONTACT_86599] )  
• If applicable, record information from standard of care kidney biopsy report s   
• Record treatments  of graft rejection  epi[INVESTIGATOR_1841]  (PE, IVIg, dialysis, other)  
• Record  current  immunosuppressive medication  
• Record and report AEs  caused by [CONTACT_802896] a clinically significant safety 
lab value   
 
 
HansaBiopharma  Date:  [ADDRESS_1108382]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
20 (43) 6. STUDY ASSESSMENT S 
6.1 Assessments related to Primary Endpoint  
The time points for all study assessments are shown in the study flow  chart ( Table 2). 
Laboratory sampling, shipment, and analysis will be described in detail in the lab oratory  
manual.  
6.1.[ADDRESS_1108383] ongoing dialysis period reported.   
6.2 Asses sments related to Secondary Endpoin ts 
6.2.1 Patient survival  
Overall patient survival is defined as time from transplantation to death for any cause . If 
applicable, information on time and cause of death will be recorded.  
6.2.2 Kidney function  
Kidney function will be evaluated by P -creatinine  and calculation of estimated filtration rate 
(eGFR) by [CONTACT_86605] /CKD -EPI [INVESTIGATOR_14420]  (performed by  [CONTACT_2728]).  Proteinuria will be measured 
by [CONTACT_5230].  The s amples will be taken at the time  points  presented in the study flow chart.  
Creatinine and proteinuria results from graft rejection epi[INVESTIGATOR_802876] [ADDRESS_1108384] of care kidney biopsies are performed for any reason , at any time -point , e.g. 
suspected rejections, information will be collected and recorded in the CRF.  
6.2.4 Graft  rejection epi[INVESTIGATOR_802877],  following Banff 
classification . 
6.2.5 Treatment of graft rejection epi[INVESTIGATOR_1865] s 
Information about treatments of graft rejection epi[INVESTIGATOR_802875] ( e.g dialysis, 
plasmapheresis and  medications) . 
HansaBiopharma  Date:  [ADDRESS_1108385]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
21 (43) 6.2.6 Comorbidity  
Information about  comorbidities that are medically relevant and registered in the subjects’ 
medical record  will be collected.  Medically relevant comorbidity are  e.g. infections, 
malignancy, diabetes mellitus and cardiovascular events . 
6.2.7 Donor Specific Antibodies (DSA)  
Samples for determination of  DSA s will be analy sed in LABScreen  single antigen  HLA class 
I and class II  assays . The assay s allow  determination of the mean fluorescence intensity (MFI) 
of antibodies in patient serum reacting to an array of individual HLA immobilized to beads . 
Analyses of DSAs  will be performed  centrally , at Hansa Biopharma  , Lund . The date and time 
of collection of each sample will be recorded on the sample  log and in the CRF.   
Samples for DSA will also be analysed by [CONTACT_5035][INVESTIGATOR_802878] . 
6.2.8 Immunogenicity  by [CONTACT_74939] -Drug Antibodies (ADA)  
Samples  for the determination  of anti -drug antibody (ADA) levels in serum  will be analysed 
for anti -imlifidase IgG using a customized imlifidase  ImmunoCAP test . The analysis will be 
performed at the central laboratory, Thermofisher Scientific, Immuno  Diagnostics, Service  
Laboratory, Alleröd, Denmark. Full details of the analytical method used,  and the analysis 
results will be detailed in a separate bioanalytical report.  The ADA samples will be taken at the 
times presented in the study flow chart. The date a nd time of collection of each sample will be 
recorded on the laboratory requisition form and in the CRF .  
6.2.9 Health Related Quality of Life Questionnaire ( HR-QoL)  
At all visits,  two patient questionnaires will  be used to  assess health related quality of life.  
European Quality of Life -5 levels  (EQ-5D-5L) and Kidney Disease Quality of Life 
Questionnaire -short form (KDQOL -SF). The individual guidelines for the questionnaires will 
be followed when administering the forms.  
6.3 Safety and other Laboratory Samples  
The investigator will review the laboratory results and evaluate and document whether the 
results are normal or abnormal and whether abnormal results are clinically or non -clinically 
significant.  The local hospi[INVESTIGATOR_802879].  The s amples will be taken at the times 
presented in the study flow chart  (Table 2). The safety  hematology and clinical chemistry tests  
will be the following:  
HansaBiopharma  Date:  [ADDRESS_1108386]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
22 (43)  
Table 3. Safety  hematology and clinical chemistry  laboratory tests  
Hematology1) 
B-Hemoglobin  
B-Differential analysis of leucocytes  
B-Thrombocytes  
Clinical Chemistry  
P-IgG 
1) May be taken as serum samples if that is standard procedure at local lab  
Virology  test for BK will also be taken at the local hospi[INVESTIGATOR_136966].  
 
7. BIOLOGICAL SAMPLING PROCEDURES  
7.[ADDRESS_1108387]  withdraws consent to the use of biological samples donated the samples will be 
disposed/destroyed, if not already analysed and documented.  
HansaBiopharma  Date:  [ADDRESS_1108388]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
23 (43) The principal investigator:  
• will ensure that subject  withdrawal of informed consent is notified immediately to Hansa 
Medical  
• will ensure that biological samples from that subject , if stored at the study site, are 
immediately identified, disposed/destructed and the action documented.  
• will ensure the laboratory(ies) holding the samples is/are informed about the withdrawn 
consent immediately and that samples are disposed/ destructed,  and the action 
documented returned to the study site.  
Hansa Biopharma  ensures the laboratory(ies) holding the samples is/are informed about the 
withdrawn consent immediately and that samples are disposed/ destructed,  and the action 
documented returned to the study site.  
In the event that analysis/research has already been performed, Hansa Biopharma  will retain 
the results and associated data for regulatory reasons,  but these will not be used in any 
subsequent analyses.  
8. ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS  
8.1 Definitions  
8.1.1 Adverse event 
An adverse event (AE) is the development of an undesirable medical condition or the 
deterioration of a pre -existing medical condition following or during exposure to a 
pharmaceutical product, whether or not considered causally related to the product. Relat ionship 
to the study drug will be deemed as not related, unlikely, possible or probable.  An undesirable 
medical condition can be symptoms (e.g., nausea and chest pain), signs (e.g., tachycardia and 
enlarged liver) or the abnormal results of an investigatio n (e.g., laboratory findings and 
electrocardiograms).  
In cases of surgical or diagnostic procedures, the condition/illness leading to such a procedure 
is considered as the AE rather than the procedure itself.  
In case of a fatality, the cause of death is considered as the AE, and the death is considered as 
its outcome.  
8.1.2 Serious adverse event 
A serious adverse event (SAE) is an AE or suspected adverse reaction (SAR) that is considered 
"serious" if, in the view of either the investigator or Hansa Biopharma , it results in any of the 
following outcomes:  
• Results in death  
• Is immediately life -threatening  
HansaBiopharma  Date:  [ADDRESS_1108389]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
24 (43) • Requires in -patient hospi[INVESTIGATOR_15574].  
• Results in persistent or significant disability or incapacity  
• Is a congenital abnormality or birth defect  
• Is an important medical event that may jeopardise the subject  or may require medical 
intervention to prevent one of the outcomes listed above .  
Life-threatening event:  An adverse event or suspected adverse reaction is considered "life -
threatening" if, in the view of either the investigator or Hansa Biopharma , its occurrence places 
the patient or subject at immediate risk of death. It does not include an adverse event or 
suspected adverse reaction that, had it occurred in a more severe form, might have caused death.   
Disability is defined as a substantial disruption in a person’s ability to conduct normal life 
functions.  
Hospi[INVESTIGATOR_11956]:  Admittance to an emergency room for observation without being admitted 
to the hospi[INVESTIGATOR_129135]. However, 
complications that occur during hospi[INVESTIGATOR_1084], and if a complication prolongs 
hospi[INVESTIGATOR_11298], the event is considered serious.  
8.2 Collection and Recording of Adverse Events  
In clinical studies, an AE/SAE can occur at any time after signing of the informed consent until 
the end of the study, including run -in or washout periods, even if no study treatment has been 
administered, e.g., an AE can be related to a procedure in the p rotocol.  
AEs will therefore be collected on the AE CRF according to the information in section 8.3. 
8.2.1 Variables  
The following variables will be recorded in the CRF for each AE; description of the AE, the 
date and time (if applicable) when the AE started and stopped, severity based on Common 
Terminol ogy Criteria  for Adverse Event s grading ( CTCAE v.4. 03) whether the AE is serious 
or not, causality rating, action taken, and outcome.  
[IP_ADDRESS]  Causality assessment    
For each reported AE the investigator will assess  the relationship of the event to study 
procedures using  the following criteria : 
• Unrelated:  applicable to an AE that occurs when the subject was not exposed to study 
treatment or another cause is obvious  (e.g. if a lab abnormality is unrelated to the study 
procedure the investigator would tick the 'unrelated' box, and then specify as to what 
they consider the lab abnormality was related to ). 
• Related : applicable to AEs where  there is a connection with study procedures .  
For SAEs , causal relationship will also be assessed for any study procedure.  
HansaBiopharma  Date:  [ADDRESS_1108390]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
25 (43) 8.2.2 Adverse Events Based on Signs and Symptoms  
When collecting AEs, the recording of diagnoses is preferred (when possible) rather than 
recording a list of signs and symptoms, for example: congestive heart failure rather than low 
ejection fraction, rales and dyspnea. However, if a diagnosis is known an d there are other signs 
or symptoms that are not generally part of the diagnosis, the diagnosis and each sign or 
symptom not part of the diagnosis will be recorded separately, for example: congestive heart 
failure and conjunctivitis.  
8.2.3 Adverse Events Based o n Examinations and Tests  
If safety  lab values are judged as clinically significant,  they will be captured as AEs and if SAE 
criteria is fulfilled they will also be SAEs . 
Wherever possible the reporting investigator uses the clinical, rather than the laboratory term 
(e.g., anaemia versus  low haemoglobin value).  
8.2.[ADDRESS_1108391] ’s last AE assessment in the study are followed up 
by [CONTACT_129159], for as long as medically indicated or the overall clinical 
outcome of the subject  is known, unless the subject  is documented as “lost to follow up ”. All 
SAEs and AEs leading to discontinuation should be followed until the event resolves, stabilizes, 
or returns to baseline.  
Reasonable attempts to obtain this information must be made and documented. Hansa 
Biopharma  retains the right to request additional information for any subject  with ongoing 
AE(s)/SAE(s) at the end of the study, if judged necessary.  
8.2.[ADDRESS_1108392], 
or to the study procedure(s) , on a separate SAE  form . In the Adverse Event form,  it will be 
added that the AE is considered serious . SAEs will be recorded from the time of informed 
consent.  
An assigned contract research organisation (Primevigilance ) will be responsible for reporting 
all SAEs to Regulatory Authorities  (RA)  in accordance with International Conference on 
Harmonisation ), Good Clinical Practice  (GCP) ) and local regulations.  
As soon as the Investigator is aware of a potential SAE he/she should contact [CONTACT_295126] e-mail no  later than [ADDRESS_1108393]  number, birth date, 
description of the SAE and a preliminary assessment of causality.  
 
HansaBiopharma  Date:  [ADDRESS_1108394]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
26 (43) Contact [CONTACT_7171]:  
CRO:  Primevigilance  
e-mail:    
 
For fatal or life -threatening adverse events where important or relevant information is missing, 
active follow up  is undertaken immediately. Investigators or other site personnel inform Hansa 
Biopharma  and monitor of any follow up  information on a previously reported SAE 
immediately but no later than within 24 hours of when he or she becomes aware of it. The 
monitor or Hansa Biopharma  will advise the investigator/study site personnel how to proceed.  
The SAE reporting procedures are detailed in the study specific Safety Management Plan. This 
plan is an agreement between the Hansa Biopharma , and Primevigilance . 
8.2.6 Reporting of Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs)  
Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) must be reported to RAs. A 
suspected serious adverse reaction is any SAE for which there is a reasonable possibility that 
the investigational product caused the adverse event. A serious adverse reacti on is considered 
"unexpected" if it is not listed in the reference safety information section of the investigator 
brochure or is not listed at the specificity or severity that has been observed.  
S[LOCATION_003]Rs with an outcome of death or which are life threatening must be reported to the 
relevant RAs within [ADDRESS_1108395] be submitted within 15 calendar 
days. The S[LOCATION_003]R reporting procedures are detailed in the study Safety Managemen t Plan. 
This plan is an agreement between the Hansa Biopharma , and  Primevigilance . Hansa 
Biopharma  will notify the appropriate RA(s) and all participating study investigators of any 
S[LOCATION_003]Rs on an expedited basis and in accordance with applicable regulations. In addition, 
Hansa Biopharma  is responsible for informing all investigators in all other ongoing studies 
involving imlifidase  about all S[LOCATION_003]Rs.  
It is the responsibility of the site investigator to promptly notify the Independent Ethics 
Committee (IEC) and other appropriate institutional regulatory bodies of all S[LOCATION_003]Rs 
received involving risk to human subjects as per their applicable requirements  
8.[ADDRESS_1108396]  
Adverse events caused by a procedure in the protocol (such as blood sampling)  or a clinically 
significant safety lab value are the only AEs that will be captured and reported  in the study . If 
the lab value  is attributable to worsening renal function , rejection,  or natural progression of 
disease, it will not be reported as AE.  
8.[ADDRESS_1108397] was performed  
at the screening visit in each study . No pregnancies were reported during the clinical studies.   

HansaBiopharma  Date:  [ADDRESS_1108398]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
27 (43) If a subject becomes pregnant during th e current study, the subject will continue in the study 
according to study protocol, if possible. A Pregnancy Report Form must be sent by [CONTACT_802897]. 
The outcome of all pregnancies (spontaneous miscarriage, elective termination, normal birth 
or congenital abnormality) will be followed up on the Pregnancy Report Form even after the 
subject has completed or discontinued the study. Primevi gilance  will follow up on pregnancy 
outcome [ADDRESS_1108399] be reported to Hansa Biopharma  and will be handled as a 
SAE. Spontaneous abortions, congenital abnormalities/birth defects are always considered to 
be SAEs and will be reported and followed up in accordance with other SAEs. Any SAE 
occurring as a result of a post -study pregnancy and co nsidered reasonably related to the study 
drug by [CONTACT_802898]  (or designee).  
9. STUDY MANAGEMENT  
9.[ADDRESS_1108400]  is entered into the study, it may be  necessary for a representative of 
Hansa Biopharma  to visit the investigational study site for a pre -study  visit to:  
Discuss with the investigator(s) (and other personnel involved with the study) their 
responsibilities with regard to protocol adherence and the responsibilities of Hansa Biopharma  
or its representatives.  
Before the first subject is entered into the study, a Hansa Biopharma  representative will review 
and discuss the requirements of the clinical study protocol and related documents with the 
investigational staff and also train them in any study specific procedures and system(s) utilized 
at a site initiation  visit. 
The principal investigator [INVESTIGATOR_295103], and that any new information relevant to the performance of this study is forwarded to 
the staff involved.  
The principal investigator [INVESTIGATOR_17459] a record of all individuals involved in the study 
(medical, nursing and other staff).  
9.[ADDRESS_1108401] regular contacts with the study 
site, including visits to:  
• Provide information and support to the investigator(s).  
• Confirm that facilities remain acceptable.  
• Confirm that the investigational team is adhering to the protocol, ICH-GCP, data are 
being accurately and timely recorded in the CRFs . 
HansaBiopharma  Date:  [ADDRESS_1108402]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
28 (43) • Perform Source Data Verification  (SDV)  (a comparison of the data in the CRFs with the 
subject ’s medical records at the hospi[INVESTIGATOR_7117], and other records relevant to the 
study) including verification of informed consent of participating patients.  
• If a subject withdraws informed consent to the use of their biological samples ; ensure this 
is reported to Hansa Biopharma  and biological samples are identified , 
disposed/destructed accordingly, and the action is documented, and reported to the 
subject . 
Hansa Biopharma  and the CRO will be available between visits if the investigator(s) or other 
staff at the center  needs information and advice about the study conduct.  
9.[ADDRESS_1108403] only be one source defined at any time for 
any data elements.   
9.4 Audit and Inspection  
The investigator will make all the study -related source data and records available at any time 
to Quality Assurance  (QA)  auditor(s) mandated by [CONTACT_295129] , or to domestic/foreign 
regulatory inspectors or representatives from IECs/IRBs who may audit/inspect the study . 
The main purposes of an audit or inspection are to assess compliance with the study  protocol 
and the principles of ICH -GCP including the Declaration of Helsinki  and all other relevant 
regulations.  
The subjects must be informed by [CONTACT_802899]/IRBs may wish to inspect their medical records. During audits/inspections the 
auditors/inspectors may copy relevant parts of the medical records. No personal identification 
apart from the screening number will appear on these copi[INVESTIGATOR_014].  
The investigator should notify without any delay of any inspection by a RA or IEC/IRB . 
9.[ADDRESS_1108404], or subjects  be enrolled.  
 
HansaBiopharma  Date:  [ADDRESS_1108405]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
29 (43) 10. DATA MANAGEMENT  
10.1 Case Report Form  
 An electronic case report form (eCRF) system provided by a CRO will be used for data 
capture. The system is validated and access at all levels to the system is granted/revoked 
following Hansa Biopharma and vendor procedures, in accordance with regulatory and 
system requirements.  
After the study database is declared clean and released to the statistician, a final copy of the 
database will be stored at Hansa Biopharma . The investigator will also receive a copy of the trial 
site’s final and locked data (including audit trail, electronic signature, meta data and queries) as 
write -protected PDF -files produced by [CONTACT_2024]. The PDF -files will be stored on a CD/DVD 
and will be provided to the investigator before access to the eCRF is  revoked.   
10.[ADDRESS_1108406] recent 
versions of the Medical Dictionary for Regulatory Activities (MedDRA) and WHO Drug will 
be used  at study closure (unless decided otherwise by [CONTACT_295129] ).  
The coding will be outsourced to a CRO.  All coding performed will be approved by [CONTACT_295132]/database lock.  
10.4 Handling of External Data  
If central laboratories or other external data transfers from vendors to Hansa Biopharma  will be 
transmitted, it will be performed in a secure environment according to a Data Transfer 
Specification.  
 
11. STATISTICAL METHODS  
All analyses will be detailed in a separate Statistical Analysis Plan (SAP). As this is a long -
term non -interventional study, it is anticipated that the first analysis of the data will occur six 
months after  the first patient first visit. Thereafter, yearly summary analysis of the data will be 
performed.  Summary analys is can also be done ad hoc  during the study.  
HansaBiopharma  Date:  [ADDRESS_1108407]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
30 (43) 11.1.1  Full Analysis Set (FAS)  
The Full Analysis  Set will be defined as all patients enrolled. Because of the non -interventional 
nature of this study no other analysis set will be defined and all data presentations and analyses 
will be based on the FAS.  
11.2 Descriptive Statistics  
The data from the clinical assessments, including demographics and other baseline 
characteristics, will be summarised by [CONTACT_802900]. Summary statistics (n, arithmetic mean, standard deviation, median, minimum 
and maximum values) will be presented for continuous variables (absolute values at each time 
point and, if relevant, changes from baseline)  and counts and, if relevant, percentages will be 
presented for categorical variables. Where appropriate, the presenta tion of results will include 
confidence intervals of estimated treatment differences and plots.  
11.[ADDRESS_1108408]’s demographics and other baseline characteristics will be summarised by  [CONTACT_802901].  
11.3.2  Concomitant Medication  
Current immunosuppressive medication will be  summarised  by [CONTACT_105281] (ATC) code and generic drug name [CONTACT_802910].  
11.3.3  Exposure and Compliance  
Since this is a non -interventional follow -up study exposure and compliance will not be 
calculated.  
11.4 Statistical analys is of Primary Endpoint  
11.5 Primary endpoint  – graft survival  
The primary endpoint, overall graft survival, is defined as time from transplantation to graft 
loss evaluated at 1, 2, [ADDRESS_1108409] dose of imlifidase . Graft loss is defined as: 
Permanent return to dialysis  for at least [ADDRESS_1108410] 
ongoing dialysis period reported .  
The primary endpoint will be analy sed by [CONTACT_8761] -Meier survival method. The overall graft 
survival will be tabulated and presented graphically with 95% confidence limits. The primary 
HansaBiopharma  Date:  [ADDRESS_1108411]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
31 (43) analysis will be based on intervals of [ADDRESS_1108412] annual summary analyses may be 
based on shorter intervals which will be defined in the SAP. The following events will be 
censored at the time of occurrence: withdrawal from the study without graf t loss, death not 
caused by [CONTACT_802902], evaluation time point (the yearly evaluations) and end of study without 
graft loss.  The KM analysis is in this study not comparative because of the non -interventional 
nature of the study. Hence, there will be no form al statistical hypothesis or testing.  
The reason for graft loss will be tabulated by [CONTACT_5586].  
Explorative analyses assessing the influence of age and other baseline characteristics may be 
defined in the SAP.  
11.6 Statistical analysis of Secondary Endpoints  
11.6.1  Graft loss not censored for death  
This endpoint is defined as the primary endpoint except that death for any cause also counts as 
a graft loss and therefore this event will not be censored. The endpoint will be analysed and 
presented as the primary endpoint.  
11.6.2  Patient survival  
Overall patient survival is defined as time from transplantation to death for any cause evaluated 
at 1, 2, 3  and 5 years. The analysis will be as for the primary endpoint. The following events 
will be censored: withdrawal from the study, evaluation time point (the yearly evaluations) and 
end of study.  
11.6.[ADDRESS_1108413] of care kidney biopsies are performed for any reason , at any time -point , e.g. 
suspected rejections, information from  the kidney biopsy report will be collected.  Data will be 
summary tabulated.  
11.6.5  Number of graft  rejection epi[INVESTIGATOR_802880] 1, 2, 3  and 5 years following Banff 
classification . 
HansaBiopharma  Date:  [ADDRESS_1108414]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
32 (43) 11.6.6  Treatment of graft rejection epi[INVESTIGATOR_802881] 1, 2, 3  and 5 years and 
by [CONTACT_173502]. Examples of treatment types are dialysis epi[INVESTIGATOR_1841], plasmapheresis and 
medication.  
11.6.7  Comorbidity  
Medical ly relevant comorbidit ies are e.g. infections, malignancy, diabetes mellitus and 
cardiovascular events. These events will be tabulated at 1, 2, 3 and 5 years by [CONTACT_802903].   
11.6.8  DSA levels  
DSA levels will be evaluated by [CONTACT_129148] -HLA at  1, 2, 3  and 5 years. The DSA levels will be 
summary tabulated and presented graphically.  
11.6.9  BK virus  
Presence of BK virus  will be tabulated at 1, 2, 3  and 5 years.  
11.6.10  ADA  
ADA will be evaluated by [CONTACT_14181] -imlifidase  IgG at 1, 2, 3  and 5 years. Data will be summary 
tabulated.  
11.6.11  Health related quality of life  
HR-QoL will be evaluated by [CONTACT_802904] -5D-5L and KDQOL at  1, 2, 3  and 5 
years. The individual guidelines for the questionnaires will be followed to create the summary 
tabulations, the details of which will be given in the SAP . 
11.7 Safety Endpoints  
11.7.1  Analysis of Adverse Events  
Only adverse events related to  study  procedures or a clinically significant safety lab value will 
be collected. If the lab value is attributable to worsening renal function , rejection,  or natural 
progression of disease, it will not be reported as an AE. 
If such events occur,  they will be listed.  
11.7.2  Analysis of Safety Variables  
All clinical safety laboratory tests will be tabulated at 1, 2, 3  and 5 years.  
11.8 Determination of Sample Size  
As this is a non -interventional follow up study, no power calculations for sample size estimation 
were performed. All patients enrolled in the selected previous or ongoing imlifidase  kidney 
transplant studies will be considered for inclusion in this study. It is anticipated that 
HansaBiopharma  Date:  [ADDRESS_1108415]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
33 (43) approximately [ADDRESS_1108416] number will depend on 
enrolment and patients’ discontinuation figures in ongoing and/or selected clinical studies  
 
12. CHANGES IN STUDY CONDUCT OR PLANNED ANALYSES  
Any changes and deviations to plans described in the protocol must be documented.  
12.1 Protocol Amendment (s) 
Any change to this protocol will be documented in a protocol amendment, issued by [CONTACT_295150] , and agreed upon by [CONTACT_295151].  Protocol Amendments and documents updated as a result of the Protocol 
Amendment must not be implemented until all approvals  (IEC/IRB and Regulatory Authorities , 
if applicable) have been obtained.  
Changes to the protocol to eliminate immediate hazard(s) to study  subjects may be implemented 
prior to IEC(s)/IRB(s) and RA approval.  
12.[ADDRESS_1108417] be reviewed, discussed and  documented  on the Protocol  Deviation Form.  Deviation 
reports and supporting  documentation will be kept in the investigator site file  and the trial 
master file.  
Hansa Biopharma will revie w all protocol deviations continuously during the course  of the 
study and assess  whether there is a need to update the protocol through an amendment  to avoid 
future deviations.  
Planned protocol deviations are not permitted.  
12.3 Changes to the Statistical Analysis Plan  
Any changes to the SAP will be described in the Clinical Study Report and/or in the Statistical 
Report.  
12.4 Premature Termination or Suspension of the Study  
If the study is prematurely terminated or suspended for any reason, the investigator/ institution 
should promptly inform the subjects  and should assure appropriate therapy and follow up . 
If the investigator terminates or suspends a study without prior agreement of Hansa Biopharma , 
the investigator should inform the institution wher e applicable. The investigator/ institution 
should promptly inform Hansa Biopharma  and should provide Hansa Biopharma  with a detailed 
written explanation of the termination or suspension.  If Hansa Biopharma  terminates or 
suspends a study, the investigator should promptly inform th e institution where applicable. In 
HansaBiopharma  Date:  [ADDRESS_1108418]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
34 (43) both cases Hansa Biopharma  will promptly inform the RA and IEC and provide the m with a 
detailed written explanation of the termination or suspension.  
If the RA or IEC terminates or suspends its approval/ favorable  opi[INVESTIGATOR_1101] a study, Hansa 
Biopharma  should inform the investigators and institutions (where applicable) and provide 
them with a detailed written explanation of the termination or suspension.  
13. REPORTING  AND PUBLICATION  
13.1 Clinical Study Report  
The results from this study will be reported in a clinical study report (CSR) within one year 
after end of study  (section 3.4). This will be prepared by [CONTACT_802905](s).  
13.[ADDRESS_1108419] the confidentiality of the proprietary 
information belonging to Hansa Biopharma . 
13.3 Publications   
13.4 Publication Policy  
At the end of the study, one or more manuscripts for joint publication may be prepared in 
collaboration between the investigator(s) offered authorship and Hansa Biopharma .  
Any external CRO  or laboratory involved in the conduct of this study has no publication rights 
regarding the study.  
13.5 Public disclosure  
The study will be registered in a public clinical trials registry i.e. the U.S. National Institutes of 
Health register ClinicalTrials. gov and /or EU Clinical Trials Register  if the study is conducted 
in Europe . 
14. ETHIC AL AND REGULATORY ASPECTS  
14.[ADDRESS_1108420] their origins in 
the World Medical Association Declaration of Helsinki , Ethical P rinciples for Medical 
Research Involving Human Subjects , Brazil 2013  in compliance with the approved protocol  
and applicable regulatory requirements.   
HansaBiopharma  Date:  [ADDRESS_1108421]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
35 (43) The responsibilities of Hansa Biopharma , the monitor and the investigator are defined in the 
ICH-GCP consolidated guideline (E6 R2) and applicable regulatory requirement s in the country 
where the study  takes place.  The investigator is responsible for adhering to the ICH -GCP 
responsibilities of investigators.  
14.2 Liabilities and Insurance  
Hansa Biopharma  is, as sponsor, responsible for ensuring appropriate general/product liability 
insurance and, as required in accordance with applicable laws and regulations, country -specific 
liability insurance coverage for claims made by a study  subject for injury arising from the 
subject’s participation in the study . 
14.3 Independent Ethics Committee (s) and Institutional Review Boards  (IRB)  
All ethical and regulatory approvals must be available before a subject is exposed to any study -
related procedure, including screening tests for eligibility.  
According to applicable regulatory requirements Hansa Biopharma  will: 
• obtain approv al from or notify the relevant (IECs) of the protocol,  any amendments, the 
Subject  Information Sheet/Informed Consent Form  and any  advertisements etc . 
• send periodic updates to the IEC(s) if applicable  
• provide Investigator(s) with an accurate and complete record of all submissions to  the 
local IEC. The copi[INVESTIGATOR_802882].  
Hansa medical  will keep an updated list of submission and approval dates of all do cuments 
submitted to IEC(s). 
14.4 Regulatory Authorit y(ies)  
According to applicable regulatory requirements Hansa Biopharma  will send required 
documents to the Regulatory Authorities. Hansa Biopharma  will keep an audited list of 
submission and approval dates of all  documents submitted to RAs.  
14.[ADDRESS_1108422]  be kept in the Investigator File.  
HansaBiopharma  Date:  [ADDRESS_1108423]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
36 (43) The subject will receive a copy of the Subject Information and his/her signed Informed Consent 
Form.  
If new information becomes available that may be relevant to the study  subject’s willingness to 
continue participation in the study , a new Subject Information and Informed Consent Form will 
be forwarded to the IEC(s)/IRB(s) (and Regulatory Authorities , if required). The study  subjects 
will be informed about this new information and re -consent will be obtained.  
14.[ADDRESS_1108424] all 
documents and records required to be maintained by [CONTACT_093], including but not limited 
to medical records (office, clinic, or hospi[INVESTIGATOR_307]) .  The clinical study site will permit access to such 
records.  
15. ARCHIVING  
15.[ADDRESS_1108425] be notified. If the 
investigator retires and the documents can no longer be archived by [CONTACT_779], Hansa Biopharma  
can arrange having the Investigator File archived at an external archive.  
HansaBiopharma  Date:  [ADDRESS_1108426]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
37 (43) 15.2 Trial  Master File  
Hansa Biopharma  will archive the Trial  Master File in accordance with ICH -GCP and 
applicable regulatory requirements.  
HansaBiopharma  Date:  [ADDRESS_1108427]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
38 (43) 16. REFERENCES  
EMA Guideline on clinical investigation of immunosuppressants for solid organ transplantation, EMA. 
2008.  
Haas, M., A. Loupy, C. Lefaucheur, C. Roufosse, D. Glotz, D. Seron, B. J. Nankivell, P. F. Halloran, R. 
B. Colvin, E. Akalin, N. Alachkar, S. Bagnasco, Y. Bouatou, J. U. Becker, L. D. Cornell, J. P. 
D. van Huyen, I. W. Gibson, E. S. Kraus, R. B. Mannon, M.  Naesens, V. Nickeleit, P. Nickerson, 
D. L. Segev, H. K. Singh, M. Stegall, P. Randhawa, L. Racusen, K. Solez, and M. Mengel. 
2018. 'The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T 
cell-mediated rejection, antibody -mediated rejection, and prospects for integrative endpoints for 
next-generation clinical trials', Am J Transplant , 18: 293 -307. 
Iyer, S. P., L. E. Nikkel, K. K. Nishiyama, E. Dworakowski, S. Cremers, C. Zhang, D. J. McMahon, S. 
Boutroy, X. S. Liu, L. E. Ratner, D. J. Cohen, X. E. Guo, E. Shane, and T. L. Nickolas. 2014. 
'Kidney Transplantation with Early Corticosteroid Withdrawal: Paradoxical Effects at the 
Central and Peripheral Skeleton', J Am Soc Nephrol : 1331 -41. 
Montgomery, R. A., A. A. Zachary, L. E. Ratner, D. L. Segev, J. M. Hiller, J. Houp, M. Cooper, L. 
Kavoussi, T. Jarrett, J. Burdick, W. R. Maley, J. K. Melancon, T. Kozlowski, C. E. Simpkins, 
M. Phillips, A. Desai, V. Collins, B. Reeb, E. Kraus, H. Rabb, M.  S. Leffell, and D. S. Warren. 
2005. 'Clinical results from transplanting incompatible live kidney donor/recipi[INVESTIGATOR_802883]', JAMA , 294: 1655 -63. 
Montgomery, R. A., B. E. Lonze, K. E. King, E. S. Kraus, L. M. Kucirka, J. E. Locke, D. S. Warren, C. 
E. Simpkins, N. N. Dagher, A. L. Singer, A. A. Zachary, and D. L. Segev. 2011. 'Desensitization 
in HLA -incompatible kidney recipi[INVESTIGATOR_802884]', N Engl J Med , 365: 318 -26. 
Orandi, B. J., J. M. Garonzik -Wang, A. B. Massie, A. A. Zachary, J. R. Montgomery, K. J. Van 
Arendonk, M. D. Stegall, S. C. Jordan, J. Oberholzer, T. B. Dunn, L. E. Ratner, S. Kapur, R. P. 
Pelletier, J. P. Roberts, M. L. Melcher, P. Singh, D. L. Sudan, M. P. Posner, J. M. El -Amm, R. 
Shapi[INVESTIGATOR_2152], M. Cooper, G. S. Lipkowitz, M. A. Rees, C. L. Marsh, B. R. Sankari, D. A. Gerber, P. 
W. Nelson, J. Wellen, A. Bozorgzadeh, A. O. Gaber, R. A. Montgomery, and D. L. Segev. 2014. 
'Quantifying the risk of incompatible kidn ey transplantation: a multicenter study', Am J 
Transplant , 14: 1573 -80. 
Orandi, B. J., X. Luo, A. B. Massie, J. M. Garonzik -Wang, B. E. Lonze, R. Ahmed, K. J. Van Arendonk, 
M. D. Stegall, S. C. Jordan, J. Oberholzer, T. B. Dunn, L. E. Ratner, S. Kapur, R. P. Pelletier, 
J. P. Roberts, M. L. Melcher, P. Singh, D. L. Sudan, M. P.  Posner, J. M. El -Amm, R. Shapi[INVESTIGATOR_2152], 
M. Cooper, G. S. Lipkowitz, M. A. Rees, C. L. Marsh, B. R. Sankari, D. A. Gerber, P. W. 
Nelson, J. Wellen, A. Bozorgzadeh, A. O. Gaber, R. A. Montgomery, and D. L. Segev. 2016. 
'Survival Benefit with Kidney Transplants fr om HLA -Incompatible Live Donors', N Engl J 
Med, 374: 940 -50. 
Wenig, K., L. Chatwell, U. von Pawel -Rammingen, L. Bjorck, R. Huber, and P. Sondermann. 2004. 
'Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity 
for IgG', Proc Natl Acad Sci U S A , 101: [ZIP_CODE] -6. 
Vincents, B., U. von Pawel -Rammingen, L. Bjorck, and M. Abrahamson. 2004. 'Enzymatic 
characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease 
with strict specificity for IgG cleavage due to exosite binding', Biochemistry , 43: [ZIP_CODE] -9. 
Vo, A. A., J. Petrozzino, K. Yeung, A. Sinha, J. Kahwaji, A. Peng, R. Villicana, J. Mackowiak, and S. 
C. Jordan. 2013. 'Efficacy, outcomes, and cost -effectiveness of desensitization using IVIG and 
rituximab', Transplantation , 95: 852 -8. 
von Pawel -Rammingen, U., B. P. Johansson, and L. Bjorck. 2002. 'IdeS, a novel streptococcal cysteine 
proteinase with unique specificity for immunoglobulin G', EMBO J , 21: 1607 -15. 
 
HansaBiopharma  Date:  [ADDRESS_1108428]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
39 (43) 17. APPENDIX 1  
Protocol revision his tory including Summary of Changes   
Protocol 
Version  Date  Including 
Amendment 
Type and No. Overall Rationale for  Changes  
1.0 03 Apr 2018       N/A Initial approved protocol  
 
2.0 20 Jun 2018  Non-
substantial 
01 • Assessment of Quality of Life Questionnaires 
were changed, it was decided to use two instead 
of three questionnaires.  
• Kidney biopsy data will be recorded directly in 
CRF instead of retrieved from the biopsy 
reports.  
• Any version of Banff classification can be used 
for classification of acute rejection epi[INVESTIGATOR_1841].  
• EudraCT number on first page is removed since 
the study was not submitted to any European 
regulatory authority.  
 
3.0 27 Sep 2020  Non -
substantial 
02 • The method of data collection will be  changed 
from paper CRF to electronic CRF .  
• A study visit can be performed remotely  if a 
subject is not able to visit the site.   
• Clarify the wordings “acute rejection epi[INVESTIGATOR_1865]” 
and “DSA rebound” by [CONTACT_802886] 
“graft rejection epi[INVESTIGATOR_1865]”.  
• Clarify that creatinine and proteinuria results 
from graft rejection epi[INVESTIGATOR_802885] [ADDRESS_1108429].  
4.0 22 NOV 2021  Non-
substantial 
03 • Updates due to change in CRO responsible for 
SAE and S[LOCATION_003]R handling . 
 
 
 
 
HansaBiopharma  Date:  [ADDRESS_1108430]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
40 (43) Protocol AMENDMENT NUMBER 0 3 Summary:  
AMENDMENT TYPE:  
This amendment is considered to be  non-substantial because it neither significantly impacts 
the safety or physical/mental integrity of participants nor the scientific value of the trial.  
RATIONALE FOR THE  AMENDMENT:  
The protocol is amended in response to a change in the CRO responsible for the SAE and 
S[LOCATION_003]R handling . 
AMENDED SECTIONS IN THE PROTOCOL : 
Details of the changes to the protocol are shown below. Changes to the text are shown in 
strike through  text and new text in underlined italics . The sections refer to the study protocol 
Final Version 3.0 including Amendment 02, dated 27 SEP 2020.  
 
1 CHANGE OF CRO RESPONSIBLE FOR SAE/S[LOCATION_003]R REPORTING  
Rationale  
The CRO handling the SAE and S[LOCATION_003]R reporting have been replaced.  
1.[ADDRESS_1108431] research organisation  (Drug Safety Navigator, DSN) will be responsible 
for reporting all SAEs to Regulatory Authorities (RA) in accordance with International 
Conference on Harmonisation, Good Clinical Practice (GCP) and local regulations.  
As soon as the Investigator is aware of a potential SAE he/she should contact [CONTACT_802906] e -mail 
no later than [ADDRESS_1108432] Information:  
CRO:  Drug Safety Navigator (DSN)  
e-mail:    
 

HansaBiopharma  Date:  [ADDRESS_1108433]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
41 (43) For fatal or life -threatening adverse events where important or relevant information is 
missing, active follow up is undertaken immediately. Investigators or other site personnel 
inform Hansa Biopharma and monitor of any follow up information on a previously reported 
SAE immediately but no later than within 24 hours of when he or she becomes aware of it. 
The monitor or H ansa Biopharma will advise the investigator/study site personnel how to 
proceed.  
The SAE reporting procedures are detailed in the study specific Safety Management Plan. 
This plan is an agreement between the Hansa Biopharma, and DSN.  
 
Changed to  
--- 
An assigned contract research organisation ( Drug Safety Navigator, DSN  Primevigilance ) 
will be responsible for reporting all SAEs to Regulatory Authorities (RA) in accordance with 
International Conference on Harmonisation, Good Clinical Practice (GCP) and local 
regulations.  
As soon as the Investigator is aware of a potential SAE he/she should contact [CONTACT_802907] e-mail no later than [ADDRESS_1108434] Information:  
CRO:  Drug Safety Navigator (DSN)  Primevigilance  
e-mail:    
 
For fatal or life -threatening adverse events where important or relevant information is 
missing, active follow up is undertaken immediately. Investigators or other site personnel 
inform Hansa Biopharma and monitor of any follow up information on a previously reported 
SAE immediately but no later than within 24 hours of when he or she becomes aware of it. 
The monitor or Hansa Biopharma will advise the investigator/study site personnel how to 
proceed.  
The SAE reporting procedures are detailed in the study specific Safety Management Plan. 
This plan is an agreement between the Hansa Biopharma, and DSN  Primevigilance . 
 
1.2 Amended Section  
Section 8.2.6, Reporting of Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs)  

HansaBiopharma  Date:  [ADDRESS_1108435]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
42 (43) Changed from  
--- 
S[LOCATION_003]Rs with an outcome of death or which are life threatening must be reported to the 
relevant RAs within [ADDRESS_1108436] be submitted within 15 calendar 
days. The S[LOCATION_003]R reporting procedures are detailed in the study Safety Managemen t Plan. 
This plan is an agreement between the Hansa Biopharma , and Drug Safety Navigator. Hansa 
Biopharma will notify the appropriate RA(s) and all participating study investigators of any 
S[LOCATION_003]Rs on an expedited basis and in accordance with applicable regulations. In addition, 
Hansa Biopharma is responsible for informing all investigators in all other ongoing studies 
involving imlifidase about all S[LOCATION_003]Rs.  
--- 
 
Changed to  
--- 
S[LOCATION_003]Rs with an outcome of death or which are life threatening must be reported to the 
relevant RAs within [ADDRESS_1108437] be submitted within 15 calendar 
days. The S[LOCATION_003]R reporting procedures are detailed in the study Safety Managemen t Plan. 
This plan is an agreement between the Hansa Biopharma , and Drug Safety Navigator  
Primevigilance . Hansa Biopharma will notify the appropriate RA(s) and all participating 
study investigators of any S[LOCATION_003]Rs on an expedited basis and in accordance w ith applicable 
regulations. In addition, Hansa Biopharma is responsible for informing all investigators in all 
other ongoing studies involving imlifidase about all S[LOCATION_003]Rs.  
--- 
 
1.[ADDRESS_1108438] within two weeks of lea rning of the 
pregnancy. The outcome of all pregnancies (spontaneous miscarriage, elective termination, 
normal birth or congenital abnormality) will be followed up on the Pregnancy Report Form 
even after the subject has completed or discontinued the study. Drug Safety Navigator will 
follow up on pregnancy outcome 4 weeks after the projected due date.  
--- 
 
HansaBiopharma  Date:  [ADDRESS_1108439]:   IdeS transplantation     Version:  4.0 incl. Amend 0 3 
Clinical Trial Protocol No: 17 -HMedIdeS -14 Doc No. :     2018 -002 
 
43 (43) Changed to  
--- 
If a subject becomes pregnant during the current study, the subject will continue in the study 
according to study protocol, if possible. A Pregnancy Report Form must be sent by [CONTACT_802908]. The outcome of all pregnancies (spontaneous miscarriage, elective 
termination, normal birth  or congenital abnormality) will be followed up on the Pregnancy 
Report Form even after the subject has completed or discontinued the study. Drug Safety 
Navigator  Primevigilance  will follow up on pregnancy outcome 4 weeks after the projected 
due date.  
--- 
 
 